Glucotrol XL Related Published Studies
Well-designed clinical trials related to Glucotrol XL (Glipizide)
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With
Type 2 Diabetes and Coronary Artery Disease. [2012]
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. [2011.09]
Meal fat storage in subcutaneous adipose tissue: comparison of pioglitazone and glipizide treatment of type 2 diabetes. [2010.10]
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. [2007.03]
Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes. [2007.03]
Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study. [2006.09]
Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance. [2006.06]
Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. [2006.03]
Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. [2006]
Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. [2006]
Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. [2005.05]
Effects of glipizide GITS and glibenclamide on metabolic control, hepatic glucose production, and insulin secretion in patients with type 2 diabetes. [2004.05]
Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes. [2004.04]
Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 diabetes: new insights on mechanisms of action. [2003.05]
Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. [2003.03]
Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. [2002.12]
Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus. [2002.06]
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. [2001.06]
Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. [2001.05]
Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes. [2000.12]
A bioequivalence study of two brands of glipizide tablets. [2000.03]
Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus. [2000.03]
Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). [1998.04]
Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM. [1997.06]
Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. [1997.04]
The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM. [1996.08]
Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. [1995.07]
Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. [1995.02]
Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. [1994.12]
Effect of insulin-glipizide combination on skeletal muscle capillary basement membrane width in diabetic patients. [1994.11]
Lack of interaction between glipizide and co-trimoxazole. [1994.10]
One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. [1994.07]
Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months. [1994.01]
Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus. [1993.11]
Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. [1993.03]
The effect of stress on glycemic control in patients with type II diabetes during glyburide and glipizide therapy. [1993.03]
The use of glipizide combined with intensive insulin treatment for the induction of remissions in new onset adult type I diabetes. [1993]
Glyburide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus. [1992.11]
Evaluation of glipizide and glyburide in a health maintenance organization. [1992.10]
Benefits and risks with glyburide and glipizide in elderly NIDDM patients. [1992.01]
Enhancement of absorption and effect of glipizide by magnesium hydroxide. [1991.01]
Acute effect of glipizide on glucose tolerance in obesity and diabetes mellitus (NIDDM). [1991]
Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide. [1991]
The effect of cholestyramine and activated charcoal on glipizide absorption. [1990.11]
Metabolic effects of combination glipizide and human proinsulin treatment in NIDDM. [1990.08]
[Effect of glipizide on glycemic control and peripheral insulin sensitivity in type 1 diabetics] [1990.03]
Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients. [1990.02]
An evaluation of the therapeutic effects and dosage equivalence of glyburide and glipizide. [1990.02]
Multicenter comparison of glyburide and glipizide in the treatment of non-insulin-dependent diabetes mellitus. [1988]
The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. [1987.11]
Lack of primary effect of sulphonylurea (glipizide) on plasma lipoproteins and insulin action in former type 2 diabetics with attenuated insulin secretion. [1987]
Disposition and hypoglycaemic action of glipizide in diabetic patients given a single dose of nifedipine. [1987]
Well-designed clinical trials possibly related to Glucotrol XL (Glipizide)
Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects. [2011.05]
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. [2010.03.16]
Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia. [2009.11]
Safe and Simple Emergency Department Discharge Therapy for Type 2 Diabetes Patients with Severe Hyperglycemia. [2009.07.20]
KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. [2009.02]
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. [2008.12]
Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice. [2007.09]
Sitagliptin: a novel drug for the treatment of type 2 diabetes. [2007.09]
Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? [2007.07]
Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift? (July/August). [2007.05.29]
Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system. [2007.04]
Reproducibility of renal function measurements in adult men with diabetic nephropathy: research and clinical implications. [2007]
A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. [2005.07]
Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study. [2005.05]
Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study. [2005.04]
Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia. [2004.09]
Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes. [2003.11]
Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. [2003.11]
Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. [2003.05]
Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure. [2003.05]
Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues. [2002.12]
Improved glucose control decreases the interaction of plasma low-density lipoproteins with arterial proteoglycans. [2002.10]
Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. [2002.08]
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. [2001.11]
Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. [2001.08]
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. [2000.01]
Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes? [1999.11]
The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). [1999.09]
United Kingdom prospective diabetes study (UKPDS): what now or so what? [1999.01]
Valuing quality of life and improvements in glycemic control in people with type 2 diabetes. [1998.12]
Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. [1998.11.04]
Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus. [1998.03]
A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. [1998.01.14]
Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue. [1997.12]
[Effect of sanhuang jiangtang recipe on insulin peripheral resistance in type II diabetics] [1997.10]
Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. [1997.01.27]
Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. [1996.12]
The effect on metabolic control of second-generation sulfonylurea drugs in patients with NIDDM after secondary failure to first-generation agents. [1996.10]
The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM. [1996.01.01]
Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. [1995.08]
Prolongation of near-normoglycemic remission in black NIDDM subjects with chronic low-dose sulfonylurea treatment. [1995.04]
Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. [1995.03]
Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. [1994.10]
Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. [1994.05.11]
Metabolic clearance rate of insulin in type 2 diabetic patients treated with combined insulin and sulfonylurea therapy. [1994.03]
Reduction of hyperglycemia after oral glucose load by the new alpha 2-adrenergic receptor antagonist SL 84.0418 in healthy subjects. [1994.03]
What is the benefit of increasing the sulfonylurea dose? [1993.02.01]
Chronic sulfonylurea therapy augments basal and meal-stimulated insulin secretion while attenuating insulin responses to sulfonylurea per se. [1992.11]
Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM) [1992.11]
|
